Login to Your Account



It takes two: Regado's start-stop clotbuster draws $60M for trials

By Randy Osborne
Staff Writer

Friday, April 11, 2014
Regado Biosciences Inc. aims to fuel with $60 million in fresh funding the phase III trial begun last year, testing the anticoagulant REG1 in patients undergoing percutaneous coronary intervention (PCI).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription